Tubulis is a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors. It combines proprietary P5 and Alco5 conjugation chemistry with Tubutecan payloads to build ultra-stable, homogeneous ADCs. Lead candidate TUB-040 targets NaPi2b in platinum-resistant ovarian cancer and lung adenocarcinoma; TUB-030 targets 5T4. Founded in 2019 as a spin-off from the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin and Ludwig Maximilians University (LMU) in Munich, Tubulis was acquired by Gilead Sciences in May 2026 for $3.15 billion upfront plus up to $1.85 billion in milestones, and now operates as The Tubulis ADC Innovation Center.
Tubulis has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
51–200
Total Funding
$623.5M
6 rounds
Gilead completed acquisition of Tubulis: $3.15B upfront, up to $1.85B in milestones, all equity acquired.
Full exit for all holders — no ongoing secondary market in Tubulis equity.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $623.5M across 6 rounds
Last updated 08-19-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Oct 30, 2025 | Series C Second Close Press release | $42M | — | Venrock Healthcare Capital Partners |
| Oct 15, 2025 | Series C | $361M | — | Venrock Healthcare Capital Partners |
| Mar 14, 2024 | Series B2 Press release | $138.8M | — | EQT Life Sciences, Nextech Invest |
Dominik Schumacher
Co-Founder & Chief Executive Officer
Jonas Helma-Smets
Co-Founder & Chief Scientific Officer
Matthew Norkunas
Chief Financial Officer & President, Tubulis Inc.
Ingo Lehrke
Chief Business Officer
Günter Fingerle-Rowson
Chief Medical Officer
Björn Hock
Chief Development Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Araris Biotech
Swiss biotech developing next-generation site-specific ADCs using its AraLinQ platform to conjugate payloads to native IgG antibodies without antibody engineering.
Sutro Biopharma
US clinical-stage biotech developing next-generation ADCs using its XpressCF cell-free protein synthesis and site-specific conjugation platforms.
Alentis Therapeutics
Swiss clinical-stage biotech developing Claudin-1 targeted antibodies and ADCs for solid tumors and fibrotic diseases.
Adcytherix
French biotech developing next-generation ADCs with novel cytotoxic payloads, seeded in 2024 by Pontifax Venture Capital.
Mersana Therapeutics
US biotech developing ADCs using its Dolaflexin and Immunosynthen platforms; competes with Tubulis in next-generation linker-payload chemistry.
Daiichi Sankyo
Japanese pharma leader in ADC therapeutics (Enhertu, Datroway); sets the commercial benchmark for solid-tumor ADCs that Tubulis competes against.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.